NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

NCT07563829 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Malignant Neoplasm

Interventions

DRUG: NPX372

Sponsor

NextPoint Therapeutics, Inc.